Amicus CEO Buys 75k Shares at 50% Discount, Betting on PKU Phase‑3 Breakthrough
Amicus Therapeutics CEO buys shares at 50% discount, boosting confidence in Phase‑3 mepolizumab for PKU; insider move signals potential breakthrough approval and market shift.
4 minutes to read